Our research team is a group of dedicated scientists from various disciplines who collaborate to develop new medicines and technologies to transform patients’ lives.
Walter Perkins, Ph.D.
Chief Technology Officer
Walter joined Insmed in December 2010 in connection with the business combination between Insmed and Transave. Prior to this, Walter joined Transave in 2002 and served as Chief Technology Officer. Walter has over 25 years’ experience utilizing nanoparticle drug delivery systems for multiple routes of administration including inhalation and has authored 80 scientific publications and U.S. patent applications.
Prior to Transave, Walter spent 15 years with The Liposome Company (later a part of Elan Drug Delivery), where he was involved in the design of several lipid-based drug delivery systems, including an artificial lung surfactant formulation, and helped in the characterization, development, and launch of the company’s two commercial products Abelcet® and Myocet®. As part of Elan’s Drug Delivery Division, Walter played a lead role in the implementation of liposome technology in both inter-divisional projects and corporate partnerships. Walter received his bachelor and doctoral degrees in Biophysical Chemistry from the University of Virginia, where he studied liposomes as model membrane systems.
The Research Team
Our research team is led by Walter Perkins, Ph.D. and is made up of a group of dedicated scientists who have experience in biochemistry/biophysics, biology, immunology, microbiology, chemistry, aerosol science, bioanalytical and formulation design. By coordinating their many disciplines, this team works with a profound sense of urgency and compassion to bring forth new technologies and medicines in therapeutic areas with the greatest potential to make a difference in patients’ lives. The team applies their expertise and skills to lead innovation across our pipeline – from discovering new therapies for hard-to-treat diseases to optimizing formulation and delivery design.